Compare Heron Therapeutics Inc (HRTX) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.65 (market cap $7.77B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is far larger — about 104.9× Heron Therapeutics Inc's market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| HRTX | PDBC | |
|---|---|---|
Market Cap | $74.04M | $7.77B |
Volume | 3,668,095 | 4,055,996 |
Sector | Health | — |
52-Week High | $1.49 | $20.10 |
52-Week Low | $0.27 | $13.16 |
Typical Hold Time | 35 Days | 56 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
PDBC trades at $19.41, down 0.26% with neutral technical signals from moving averages and oscillators. The ETF has demonstrated strong performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows mixed sentiment with significant short interest growth of 215.4% in September offset by new institutional positions from firms like Arlington Capital and Advisortrust Partners.
The commodity ETF faces a complex outlook with potential upside from ongoing geopolitical tensions and defensive portfolio rotation, but risks include the sharp increase in short interest and commodity market volatility. Analyst sentiment remains cautiously optimistic given the fund's strong 2026 performance and defensive characteristics in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
